Expert Perspectives on Extended Follow-Up Data from ALPINE
Chaitra S. Ujjani, MD examines extended follow-up data from the ALPINE trial, emphasizing noteworthy findings from the sensitivity and safety analyses recently presented at ASH 2023.
EP: 1.Navigating Frontline Treatment Options in CLL
EP: 2.Updates from SEQUOIA and ELEVATE-TN: Impact on CLL Treatment Selection in the First-Line Setting
EP: 3.Expert Perspectives on Extended Follow-Up Data from ALPINE
EP: 4.Insights from ELEVATE-RR and Considerations for Combination Therapy in R/R CLL
EP: 5.Navigating Therapy Options in R/R CLL: Consideration Factors for Treatment Selection
EP: 6.Treatment Strategies for Managing BTK Inhibitor Intolerance in CLL
EP: 7.Expert Perspectives on Emerging Data Surrounding BTK Inhibitor Resistance in CLL
This is a video synopsis/summary of a News Network involving Richard Furman, MD, and Chaitra S. Ujjani, MD.
Ujjani discusses Bruton tyrosine kinase (BTK) inhibitor selection in the relapse/refractory setting, focusing on the ALPINE study comparing zanubrutinib and ibrutinib. Results reveal a significant progression-free survival benefit with zanubrutinib (66%) over ibrutinib (50%) at 3 years, particularly in high-risk patients with TP53 mutations. Unexpectedly, sensitivity analyses show a progression-free survival difference even when patients stay on either inhibitor.
Regarding safety, zanubrutinib exhibits fewer cardiac adverse events, especially atrial fibrillation, making it favorable for older patients with cardiac comorbidities. The ease of zanubrutinib on patients, with minimal need for dose modifications, distinguishes its safety profile. Ujjani speculates on factors like BTK inhibition selection contributing to the unexpected outcome.
In summary, the ALPINE study highlights zanubrutinib’s efficacy and safety advantages over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, impacting treatment decisions in this setting.
This summary was AI-generated and reviewed by OncLive® editorial staff.
